FRANKLIN LAKES, N.J. - BD (Becton, Dickinson and Company) (NYSE: BDX), a prominent global medical technology firm, announced the release of its BD® Intraosseous Vascular Access System. This medical device is designed to rapidly deliver fluids or medication in urgent care scenarios where traditional intravenous (IV) access is not feasible.
The system provides an alternative method for medical professionals to administer treatments by inserting a needle into a patient's bone marrow cavity. It is engineered for swift intervention across a variety of emergency care settings and can be used for both adult and pediatric patients.
BD’s new system distinguishes itself from other products in the market with features like the ability to attach the extension set before placement and integrated passive needle tip safety to protect against needlestick injuries. The system offers a selection of five needle lengths to accommodate different patient sizes and an innovative powered driver with a rechargeable battery, which BD claims can last up to 12 times longer than non-rechargeable competitors. A multi-light battery indicator is included to provide immediate battery status confirmation.
Eric Borin, worldwide president of Medication Delivery Solutions at BD, highlighted the importance of the innovation, stating that it builds on the company's commitment to improving patient outcomes in emergency health situations. He emphasized the system’s role in providing stable and safe medication or fluid administration with a high success rate for placement.
The BD® IO System is now available for purchase in the United States. It is presented as a solution that offers a less than one percent chance of serious complications and is twice as likely to be successfully placed in critical situations compared to peripheral IVs or central venous catheters.
BD is recognized as one of the largest medical technology companies globally, with over 70,000 employees and a presence in virtually every country. The company focuses on advancing medical discovery, diagnostics, and care delivery, aiming to support healthcare professionals and improve safety and efficiency in clinical processes.
This announcement is based on a press release statement from BD.
In other recent news, global medical technology firm Becton Dickinson (NYSE:BDX) (BD) announced several significant developments. The company reported robust fiscal third-quarter results, with a 5.2% organic revenue growth and earnings per share (EPS) of $3.50, marking an 18% year-on-year increase. BD revised its organic growth guidance to between 5% and 5.25%, down from the previous range of 5.5% to 6.25%, but raised the EPS forecast for fiscal 2024 to a range of $13.05 to $13.15.
BD has also settled a significant portion of its hernia product litigation, aiming to reduce uncertainty for stakeholders involved in the settled cases. In terms of acquisitions, BD completed the purchase of Edwards Lifesciences (NYSE:EW)' Critical Care product group, now known as BD Advanced Patient Monitoring, to enhance its smart connected care solutions with advanced monitoring technologies and AI-driven clinical decision tools.
On the analyst front, Citi upgraded BD from Neutral to Buy, setting a new price target of $275. Jefferies, on the other hand, adjusted its price target for BD to $305 from $315, maintaining a Buy rating. Leadership changes included the appointment of Thomas Spoerel as Senior Vice President, CFO Regions, and Michael Feld as executive vice president and president of BD's Life Sciences segment.
Additionally, BD, in collaboration with Hamilton Robotics, introduced a new series of high-throughput, robotics-compatible reagent kits designed to automate and standardize the preparation of genetic material for sequencing. These are the recent developments at Becton Dickinson.
InvestingPro Insights
BD's launch of the Intraosseous Vascular Access System aligns well with its position as a key player in the Healthcare Equipment & Supplies industry, as highlighted by InvestingPro Tips. This innovation reinforces BD's commitment to advancing medical technology and improving patient care, which is crucial for maintaining its market leadership.
According to InvestingPro data, BD's market capitalization stands at $68.65 billion, reflecting its significant presence in the healthcare sector. The company's revenue for the last twelve months as of Q3 2024 was $19.83 billion, with a revenue growth of 4.11% over the same period. This growth trajectory supports BD's ability to invest in new product development, such as the IO Vascular Access System.
An InvestingPro Tip notes that BD has raised its dividend for 53 consecutive years, demonstrating a strong track record of financial stability and shareholder returns. This consistency in dividend growth, coupled with the company's innovative product launches, may appeal to investors looking for both income and growth potential in the healthcare sector.
For readers interested in a deeper analysis, InvestingPro offers additional tips and insights. Currently, there are 8 more InvestingPro Tips available for BD, providing a comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.